USP7-IN-18 - CAS 3052223-40-9

USP7-IN-18 (Compound X21) serves as a novel USP7 inhibitor by directly suppressing enzyme activity and modulating downstream pathways, including the newly identified PCLAF target. At concentrations of 0.25-1 μM for 24 hours, it exhibits inhibitory effects. USP7-IN-18 effectively reduces proliferation in leukemia (RS4;11) and colon cancer (MC38/CT26.WT) cells at 0.01-100 μM over 72 hours. It demonstrates high selectivity for USP7 at 2.5 μM within 0.5 hours, surpassing eight other deubiquitinating enzymes. SPR analysis shows that at 1.95-2000 nM for 3 minutes, the compound binds the catalytic domain of USP7 with a KD value of 4.9 μM.

DUB, DNA Methyltransferase, MDM-2/p53

Chromatin/Epigenetic, DNA Damage/DNA Repair, Ubiquitination, Cell Cycle/Checkpoint, Apoptosis

3052174

C30H28ClN3O3S

546.08

O=C1N(C(=O)C2C1C2(C)C)CC=3SC=4C(=NC=CC4C5=CC(Cl)=C6C=CC=CC6=C5OC7CCNCC7)C3

-20°C

Ice Packs

Small Compound